Compare Expensify Inc (EXFY) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Tempus AI — how do they compare? Expensify Inc trades at $1.77 (market cap $170.21M), while Tempus AI trades at $54.31 (market cap $10.28B). The key difference: Tempus AI is far larger — about 60.4× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| EXFY | TEM | |
|---|---|---|
Market Cap | $170.21M | $10.28B |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.33 | $103.25 |
52-Week Low | $0.75 | $42.37 |
Enterprise Value | $109.24M | $10.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.755, down 3.04% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative profitability metrics with a -14.68% net income margin. Recent developments include AI-powered expense management expansions and a $25 million stock repurchase program, indicating strategic initiatives to drive growth.
The outlook remains cautious due to persistent unprofitability despite revenue stabilization around $140 million. Investment opportunities lie in operational efficiency gains and new product integrations, but risks include competitive pressure and the challenge of achieving sustainable profitability. Analyst sentiment is divided with equal buy/hold ratings, reflecting uncertainty about the company's turnaround potential.
Tempus AI (TEM) trades at $55.62, down 5.1% over 24 hours, with a neutral technical signal and bullish moving average alignment. The company reported Q1 2026 revenue growth and an earnings beat, though it remains unprofitable with a net margin of -22.2%. Recent news highlights FDA clearances and partnerships, while analyst consensus is strongly positive with a $68.50 price target.
The outlook balances high-growth potential in AI-driven healthcare data against significant near-term losses. Investment opportunity lies in Tempus's unique data platform and expanding market reach, but risks include persistent cash burn and competitive pressures. Upside depends on achieving profitability and scaling high-margin segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
